EL7.AI
StocksMedium•31 August 2026•
1 min read

BioMarin Stock Outlook Brightens After Patent Settlement and Strategic Acquisition

Key Facts

1Jefferies analyst raised BioMarin's price target to $105, signaling a potential 60% upside.
2BioMarin reached a patent settlement with Ascendis Pharma, securing 20% royalties on U.S. sales of the drug Yuviwel.
3The company acquired Alesta Therapeutics for $275 million to expand its rare disease pipeline.

In a move reflecting optimism within the specialized biotechnology sector, Jefferies has raised its price target for BioMarin to $105, suggesting a potential 60% upside. This upgrade follows the company's global patent settlement with Ascendis Pharma, which secures BioMarin a 20% royalty on U.S. sales of the drug Yuviwel, alongside 18% royalties in the EU, Brazil, and South Korea through May 2030.

BioMarin further strengthened its rare disease market position by acquiring Alesta Therapeutics for $275 million, a strategic acquisition aimed at adding a potential oral therapy for Hypophosphatasia to its pipeline. According to analyst reports, these new royalty streams and pipeline expansions support the long-term financial stability and growth of the company, which holds a market capitalization of approximately $12.7 billion.

In a broader context, recent U.S. data showed GDP growth at 1.5% for the quarter, a factor that may influence investor sentiment toward defensive sectors like healthcare.

Open on chart